103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB3180 Introduced , by Rep. Tom Weber SYNOPSIS AS INTRODUCED: 720 ILCS 570/210 from Ch. 56 1/2, par. 1210 Amends the Illinois Controlled Substances Act. Adds Clonazolam as a Schedule IV controlled substance. LRB103 29935 RLC 56350 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB3180 Introduced , by Rep. Tom Weber SYNOPSIS AS INTRODUCED: 720 ILCS 570/210 from Ch. 56 1/2, par. 1210 720 ILCS 570/210 from Ch. 56 1/2, par. 1210 Amends the Illinois Controlled Substances Act. Adds Clonazolam as a Schedule IV controlled substance. LRB103 29935 RLC 56350 b LRB103 29935 RLC 56350 b A BILL FOR
103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB3180 Introduced , by Rep. Tom Weber SYNOPSIS AS INTRODUCED:
720 ILCS 570/210 from Ch. 56 1/2, par. 1210 720 ILCS 570/210 from Ch. 56 1/2, par. 1210
720 ILCS 570/210 from Ch. 56 1/2, par. 1210
Amends the Illinois Controlled Substances Act. Adds Clonazolam as a Schedule IV controlled substance.
LRB103 29935 RLC 56350 b LRB103 29935 RLC 56350 b
LRB103 29935 RLC 56350 b
A BILL FOR
HB3180LRB103 29935 RLC 56350 b HB3180 LRB103 29935 RLC 56350 b
HB3180 LRB103 29935 RLC 56350 b
1 AN ACT concerning criminal law.
2 Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
4 Section 5. The Illinois Controlled Substances Act is
5 amended by changing Section 210 as follows:
6 (720 ILCS 570/210) (from Ch. 56 1/2, par. 1210)
7 Sec. 210. (a) The controlled substances listed in this
8 Section are included in Schedule IV.
9 (b) Unless specifically excepted or unless listed in
10 another schedule, any material, compound, mixture, or
11 preparation containing limited quantities of any of the
12 following narcotic drugs, or their salts calculated as the
13 free anhydrous base or alkaloid, as set forth below:
14 (1) Not more than 1 milligram of difenoxin (DEA Drug
15 Code No. 9618) and not less than 25 micrograms of atropine
16 sulfate per dosage unit.
17 (2) Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1,
18 2-diphenyl-3-methyl-2-propionoxybutane).
19 (c) Unless specifically excepted or unless listed in
20 another schedule, any material, compound, mixture, or
21 preparation which contains any quantity of the following
22 substances having a potential for abuse associated with a
23 depressant effect on the central nervous system:
103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB3180 Introduced , by Rep. Tom Weber SYNOPSIS AS INTRODUCED:
720 ILCS 570/210 from Ch. 56 1/2, par. 1210 720 ILCS 570/210 from Ch. 56 1/2, par. 1210
720 ILCS 570/210 from Ch. 56 1/2, par. 1210
Amends the Illinois Controlled Substances Act. Adds Clonazolam as a Schedule IV controlled substance.
LRB103 29935 RLC 56350 b LRB103 29935 RLC 56350 b
LRB103 29935 RLC 56350 b
A BILL FOR
720 ILCS 570/210 from Ch. 56 1/2, par. 1210
LRB103 29935 RLC 56350 b
HB3180 LRB103 29935 RLC 56350 b
HB3180- 2 -LRB103 29935 RLC 56350 b HB3180 - 2 - LRB103 29935 RLC 56350 b
HB3180 - 2 - LRB103 29935 RLC 56350 b
1 (1) Alprazolam;
2 (2) Barbital;
3 (2.1) Bromazepam;
4 (2.2) Camazepam;
5 (2.3) Carisoprodol;
6 (3) Chloral Betaine;
7 (4) Chloral Hydrate;
8 (5) Chlordiazepoxide;
9 (5.1) Clobazam;
10 (6) Clonazepam;
11 (6.1) Clonazolam;
12 (7) Clorazepate;
13 (7.1) Clotiazepam;
14 (7.2) Cloxazolam;
15 (7.3) Delorazepam;
16 (8) Diazepam;
17 (8.05) Dichloralphenazone;
18 (8.1) Estazolam;
19 (9) Ethchlorvynol;
20 (10) Ethinamate;
21 (10.1) Ethyl loflazepate;
22 (10.2) Fludiazepam;
23 (10.3) Flunitrazepam;
24 (11) Flurazepam;
25 (11.1) Fospropofol;
26 (12) Halazepam;
HB3180 - 2 - LRB103 29935 RLC 56350 b
HB3180- 3 -LRB103 29935 RLC 56350 b HB3180 - 3 - LRB103 29935 RLC 56350 b
HB3180 - 3 - LRB103 29935 RLC 56350 b
1 (12.1) Haloxazolam;
2 (12.2) Ketazolam;
3 (12.3) Loprazolam;
4 (13) Lorazepam;
5 (13.1) Lormetazepam;
6 (14) Mebutamate;
7 (14.1) Medazepam;
8 (15) Meprobamate;
9 (16) Methohexital;
10 (17) Methylphenobarbital (Mephobarbital);
11 (17.1) Midazolam;
12 (17.2) Nimetazepam;
13 (17.3) Nitrazepam;
14 (17.4) Nordiazepam;
15 (18) Oxazepam;
16 (18.1) Oxazolam;
17 (19) Paraldehyde;
18 (20) Petrichloral;
19 (21) Phenobarbital;
20 (21.1) Pinazepam;
21 (22) Prazepam;
22 (22.1) Quazepam;
23 (23) Temazepam;
24 (23.1) Tetrazepam;
25 (23.2) Tramadol;
26 (24) Triazolam;
HB3180 - 3 - LRB103 29935 RLC 56350 b
HB3180- 4 -LRB103 29935 RLC 56350 b HB3180 - 4 - LRB103 29935 RLC 56350 b
HB3180 - 4 - LRB103 29935 RLC 56350 b
1 (24.5) Zaleplon;
2 (25) Zolpidem;
3 (26) Zopiclone.
4 (d) Any material, compound, mixture, or preparation which
5 contains any quantity of the following substances, including
6 its salts, isomers (whether optical, position, or geometric),
7 and salts of such isomers, whenever the existence of such
8 salts, isomers and salts of isomers is possible:
9 (1) Fenfluramine.
10 (e) Unless specifically excepted or unless listed in
11 another schedule any material, compound, mixture, or
12 preparation which contains any quantity of the following
13 substances having a stimulant effect on the central nervous
14 system, including its salts, isomers (whether optical,
15 position or geometric), and salts of such isomers whenever the
16 existence of such salts, isomers, and salts of isomers is
17 possible within the specific chemical designation:
18 (1) Cathine ((+)-norpseudoephedrine);
19 (1.1) Diethylpropion;
20 (1.2) Fencamfamin;
21 (1.3) Fenproporex;
22 (2) Mazindol;
23 (2.1) Mefenorex;
24 (3) Phentermine;
25 (4) Pemoline (including organometallic complexes and
26 chelates thereof);
HB3180 - 4 - LRB103 29935 RLC 56350 b
HB3180- 5 -LRB103 29935 RLC 56350 b HB3180 - 5 - LRB103 29935 RLC 56350 b
HB3180 - 5 - LRB103 29935 RLC 56350 b
1 (5) Pipradrol;
2 (6) SPA ((-)-1-dimethylamino-1, 2-diphenylethane);
3 (7) Modafinil;
4 (8) Sibutramine.
5 (f) Other Substances. Unless specifically excepted or
6 unless listed in another schedule, any material, compound,
7 mixture, or preparation that contains any quantity of the
8 following substance, including its salts:
9 (1) Butorphanol (including its optical isomers).
10 (g) The Department may except by rule any compound,
11 mixture, or preparation containing any depressant substance
12 listed in subsection (b) from the application of all or any
13 part of this Act if the compound, mixture, or preparation
14 contains one or more active medicinal ingredients not having a
15 depressant effect on the central nervous system, and if the
16 admixtures are included therein in combinations, quantity,
17 proportion, or concentration that vitiate the potential for
18 abuse of the substances which have a depressant effect on the
19 central nervous system.
20 (h) Except as otherwise provided in Section 216, any
21 material, compound, mixture, or preparation that contains any
22 quantity of the following substance having a stimulant effect
23 on the central nervous system, including its salts,
24 enantiomers (optical isomers) and salts of enantiomers
25 (optical isomers):
26 (1) Ephedrine, its salts, optical isomers and salts of
HB3180 - 5 - LRB103 29935 RLC 56350 b
HB3180- 6 -LRB103 29935 RLC 56350 b HB3180 - 6 - LRB103 29935 RLC 56350 b
HB3180 - 6 - LRB103 29935 RLC 56350 b
1 optical isomers.
2 (Source: P.A. 97-334, eff. 1-1-12.)
HB3180 - 6 - LRB103 29935 RLC 56350 b